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INTRODUCTION
Pulmonary surfactant is the cornerstone of the treatment
of respiratory distress syndrome (RDS) in the newborn infants.
A number of pulmonary surfactants have been developed,
but only several agents are used in the present days in the
world (1). In Korea, Surfacten
� and Exosurf
� came into the
market in 1990, and Curosurf
�in 1996. Surfacten
�and Curo-
surf
� are modified natural surfactants derived from bovine
and porcine lung, respectively. While on the other, Exosurf
�
is a purely synthetic surfactant. However, Exosurf
� has dropped
out of the market before long, and Surfacten
� imported from
Japan has been the most commonly prescribed pulmonary
surfactant for the treatment of RDS in the newborn infants
in Korea since the first clinical report by Namgung et al. (2)
and the following multi-center clinical trial by Bae et al. (3,
4). However, because of the high cost of Surfacten
�, the need
for less expensive domestic pulmonary surfactant agent has
emerged. Thereupon, Newfactan
�, a semi-synthetic pulmonary
surfactant derived from bovine lung, was co-developed by a
domestic pharmaceutical company and a medical college.
Both in vitro and in vivo studies confirmed the efficacy of
Newfactan
� (5, 6). However, the clinical data on the efficacy
of Newfactan
� are scant (7-9), especially in extremely low birth
weight infants whose survival rate has improved remarkably
recently. The initial clinical report on its efficacy in RDS was
not a comparative study, but a single agent study (7). A sin-
gle comparative study of Newfactan
� with Surfacten
� was done
so far (8). In that study, a total of 60 newborn infants were
enrolled with 30 infants in each surfactant group. There were
no differences in the efficacy in the treatment of RDS, the
incidence of complications, and mortality between Surfacten
�
and Newfactan
� groups. However, this study has some limi-
tations as the authors mentioned in the discussion. Firstly,
the number of the newborn infants enrolled was small because
only two centers participated in the study. Secondly, the study
lacks the data on the extremely low birth weight infants, espe-
cially the infants with birth weight of less than 800 g, whose
survival rate has improved dramatically recently. Therefore,
further comparative studies with the larger number of new-
born infants, especially the extremely low birth weight infants
whose birth weight was less than 1,000 g are required to verify
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Comparison of Clinical Efficacy of Newfactan
� versus Surfacten
� for the
Treatment of Respiratory Distress Syndrome in the Newborn Infants
Newfactan
� is a domestically developed, bovine lung-derived, semi-synthetic surfac-
tant. The aim of this study was to compare the clinical efficacy of Newfactan
� with
that of Surfacten
� in the treatment of respiratory distress syndrome (RDS). Newfac-
tan
� or Surfacten
� was randomly allocated to 492 newborn infants who were diag-
nosed as RDS and required surfactant instillation in four participating hospitals. The
comparisons were made individually in two subsets of infants by birth weight (<1,500
g group [n=253] and ≥1,500 g group [n=239]). Short-term responses to surfactant
and acute complications, such as the total doses of surfactant instilled, response
type, extubation rate, ventilator settings, changes in respiratory parameters, air leak,
patent ductus arteriosus, pulmonary hemorrhage, and intraventricular hemorrhage,
and mortality during the 96 hr after surfactant instillation were measured. Long-term
outcome and complications, such as total duration of intubation, bronchopulmonary
dysplasia and periventricular leukomalacia, and ultimate mortality were measured.
There were no significant differences in demographic and perinatal variables, short-
term responses to surfactant and acute complications, and long-term outcome and
complications between Newfactan
� and Surfacten
� in both birth weight groups. We
concluded that Newfactan
� was comparable to Surfacten
� in the clinical efficacy in
the treatment of RDS in both birth weight groups.
Key Words : Newfactan
�; Surfacten
�; Pulmonary Surfactants; Respiratory Distress Syndrome, Newborn
Received : 28 December 2004
Accepted : 11 April 2005592 C.W. Choi, J.H. Hwang, E.J. Yoo, et al.
the comparability of Newfactan
� to Surfacten
� in clinical effi-
cacy in the treatment of RDS. Therefore, we did a multi-cen-
ter clinical comparative study enrolled a fairly large number
of the newborn infants, especially the extremely low birth
weight infants. A total of 112 extremely low birth weight
infants were included in our subjects.
MATERIALS AND METHODS
Subjects
A total of 492 newborn infants who were admitted to the
neonatal intensive care units in four hospitals: Samsung Seoul
Hospital; Samsung Cheil Hospital; Kangnam Cha Hospital;
and Soonchunhyang University Bucheon Hospital and diag-
nosed as RDS, and judged to require pulmonary surfactant
instillation therapy between May 2002 and July 2004 were
enrolled. The diagnosis of RDS and the judgment of the re-
quirement for surfactant instillation therapy were made by the
staff neonatologists at each participating hospital. Newborn
infants who had a major congenital anomaly were excluded.
Institutional review board (Samsung Seoul Hospital, Seoul,
Korea) approved the study protocol and informed consent
was obtained from a parent before study participation. 
Study protocol
Newfactan
� or Surfacten
� was randomly allocated and in-
stilled to the newborn infants who were newly enrolled to
the study during the study period. The order of allocation
was individualized by each participating hospital. The two
surfactants were alternatively allocated in two stratified blocks
by birth weight, which are <1,500 g and ≥1,500 g block.
However, in the hospitals where the infants with a birth weight
of less than 1,500 g were in the minority, the allocation was
done without stratification.
The method of surfactant instillation was the same among
the four participating hospitals. Surfactant instillation was
used as a rescue therapy. Newfactan
�or Surfacten
�was dissolved
in 4 mL of 0.9% saline and 4 mL/kg of the dissolved solution
was instilled into the trachea via endotracheal tube by using
orogastric tube. To distribute the surfactant to the whole lung
evenly, four-position method was used. Surfactant was instilled
to a maximum of 3 doses according to the infant’s condition.
Second or third dose was given after 6 hr when the infant
became worse clinically and radiologically at the staff neona-
tologist’s discretion.
Outcome measures
The comparisons of outcome were also done by stratifying
the subject infants into two subgroups by birth weight, which
are <1,500 g group and ≥1,500 g group. Short-term responses
to surfactant and acute complications include the total doses
of surfactant instilled, response type, extubation rate, changes
in respiratory parameters, air leak, patent ductus arteriosus,
pulmonary hemorrhage, intraventricular hemorrhage, and
short-term mortality during the 96 hr after surfactant instilla-
tion. Long-term outcome and complications include the total
duration of intubation, bronchopulmonary dysplasia (BPD)
and periventricular leukomalacia, and ultimate mortality.
We chose arterial-alveolar oxygen ratio (a/APO2=PaO2/[713
×FiO2-PaCO2/0.8]) and ventilatory index (VI=mean airway
pressure×FiO2/PaO2) (10) as respiratory parameters. The
response type to surfactant was defined into three types: ‘Favor-
able’ when VI dropped below 0.047 within 6 hr after surfac-
tant instillation; ‘Relapse’ when VI rebounded above 0.047
between 6 and 96 hr after surfactant instillation among ‘favor-
able’ cases; and ‘Poor’ when VI did not drop below 0.047 with-
in 6 hr after surfactant instillation (11). When the infant was
already extubated, the response type was assigned to ‘‘Favor-
able’’, FiO2 to 21%, and mean airway pressure (MAP) to 0
cmH2O. Extubation was defined as a successful extubation
that does not require re-intubation within 7 days after the
extubation. Air leak includes pneumothrax, pneumomedi-
astinum, and pulmonary interstitial emphysema. Patent duc-
tus arteriosus was diagnosed by echocardiography and only
symptomatic cases were identified. Intraventricular hemor-
rhage and periventricular leukomalacia were diagnosed by
brain ultrasonography, and only high-grade (≥grade III) intra-
ventricular hemorrhage was identified. Periventricular leuko-
malacia was identified only in infants who survived more than
28 days after birth. Pulmonary hemorrhage was diagnosed
when the fresh blood gushed out of the endotracheal tube in
the presence of typical chest radiography finding. The diag-
nosis of BPD was made in the infants who needed supplemen-
tal oxygen at 36 wk postmenstrual age (gestational age <32
wk) or for more than 28 days after birth (gestational age ≥32
wk) with consistent radiographic change (persistent hazy opaci-
fication or cystlike pattern of density and lucency) (11). BPD
was also identified only in the infants who survived more than
28 days after birth.
Statistical methods
Statistical analyses were done by using SPSS version 11.5
(SPSS Inc. Chicago, IL, U.S.A.). All categorical variables were
expressed as percent (%) and continuous variables were ex-
pressed as mean±standard deviation. Categorical variables
between Newfactan
� group and Surfacten
� group were com-
pared by chi-square test or Fisher’s exact test. Continuous
variables were compared by Student t-test or Mann-Whitney
Utest. Repeatedly measured variables like respiratory param-
eters were compared by using repeated measures ANOVA.
P value of less than 0.05 was considered significant. The sta-
tistical analyses were supervised by a biomedical statistician
at Samsung Seoul Hospital.Clinical Efficacy of Newfactan
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RESULTS
Demographic variables
Of a total of 492 newborn infants, 224 infants were given
Newfactan
� (Newfactan
� group) and 268 infants were given
Surfacten
� (Surfacten
� group), and 253 infants had the birth
weight of less than 1,500 g (<1,500 g group) and 239 infants
had the birth weight of more than 1,500 g (≥1,500 g group).
The followings are the distribution of enrolled infants accord-
ing to the participating hospital: 180 infants in Samsung
Seoul Hospital; 156 infants in Samsung Cheil Hospital; 124
infants in Kangnam Cha Hospital; 32 infants in Soonchun-
hyang University Bucheon Hospital (Fig. 1). A total of 112
extremely low birth weight infants were included in <1,500
g group, which consisted of 13 infants with a birth weight
of <600 g, 41 infants with a birth weight of 600-799 g, and
58 infants with a birth weight of 800-1,000 g (Fig. 1).
There were no significant differences in birth weight (1,074
±255 g for Newfactan
� group versus 1,031±276 g for Sur-
facten
� group) and gestational age (28.1±2.3 vs. 28.4±2.6
wk) between Newfactan
� group and Surfacten
� group in
<1,500 g group as well as in ≥1,500 g (birth weight 2,496±
714 vs. 2,346±596 g, gestational age 35.2±3.0 vs. 34.6
±3.0 wk). There were no significant differences in sex ratio
between Newfactan
�group and Surfacten
�group in both birth
weight groups (Table 1).
Perinatal variables
There were no significant differences in perinatal variables
between Newfactan
� group and Surfacten
� group in both
<1,500 g group and ≥1,500 g group (Table 1). 
The respiratory parameters just before the surfactant instil-
lation indicating the severity of RDS, such as FiO2, MAP,
VI, and a/APO2 were not significantly different between New-
factan
� group and Surfacten
� group in both birth weight
groups (pretreatment values in Fig. 2, 3).
Short-term responses to surfactant and acute complica-
tions
In <1,500 g group, the total doses of surfactant instilled
were not significantly different between Newfactan
� group
<1,500 g (n=253)
Newfactan (n=99) p Surfacten
� (n=154)
≥1,500 g (n=239)
Newfactan (n=125) p Surfacten
� (n=114)
Birth weight (g) 1,074±255 1,031±276 0.21 2,496±714 2,346±596 0.08
Gestational age (wk) 28.4±2.6 28.1±2.3 0.19 35.2±3.0 34.6±3.0 0.10
Male sex (%) 45 (46) 85 (58) 0.08 65 (57) 70 (65) 0.21
1 min Apgar score 3.4±1.7 3.1±1.6 0.27 6.6±1.8 6.1±2.1 0.08
5 min Apgar score 6.0±1.6 5.5±2.2 0.34 8.0±1.4 7.7±1.7 0.22
Twin (%) 30 (30) 56 (36) 0.32 23 (18) 28 (25) 0.25
PPROM (%) 30 (33) 47 (33) 1.00 26 (23) 34 (31) 0.18
SGA (%) 17 (17) 22 (14) 0.54 2 (2) 4 (4) 0.35
C/S (%) 70 (72) 121 (80) 0.15 96 (79) 87 (80) 0.93
PIH (%) 19 (19) 40 (26) 0.23 6 (5) 10 (9) 0.22
Chorioamnionitis (%) 18 (27) 15 (16) 0.07 1 (1) 2 (3) 0.51
Antenatal steroid (%) 48 (52) 70 (48) 0.55 24 (20) 23 (21) 0.86
Table 1. Comparisons of demographic and perinatal variables between Newfactan
� group and Surfacten
� group
PPROM, Preterm premature rupture of membrane; SGA, Small for gestational age; C/S, Caesarean section delivery; PIH, Pregnancy induced hyper-
tension.
Hospital distribution
(Total subject infants)
Samsung Seoul
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B
Fig. 1. The distribution of total subject infants according to the participating hospitals (A) and the distribution of the infants in <1,500 g group
according to birth weight (B). The figures designate the number of infants.594 C.W. Choi, J.H. Hwang, E.J. Yoo, et al.
Fig. 2. The time courses of FiO2 and mean airway pressure (MAP) over the 96 hr after surfactant instillation between Newfactan
� group and
Surfacten
� group in <1,500 g group and ≥1,500 g group. (A) FiO2 in <1,500 g group; (B) Mean airway pressure in <1,500 g group; (C)
FiO2 in ≥1,500 g group; (D) mean airway pressure in ≥1,500 g group. There were no significant differences in the time courses of FiO2
and mean airway pressure in both <1,500 g group and ≥1,500 g group.
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Fig. 3. The time courses of arterial-alveolar oxygen ratio (a/APO2) and ventilatory index (VI) over the 96 hr after surfactant instillation between
Newfactan
� group and Surfacten
� group in <1,500 g group and ≥1,500 g group. (A) a/APO2 in <1,500 g group; (B) VI in <1,500 g group;
(C) a/APO2 in ≥1,500 g group; (D) VI in ≥1,500 g group. There were no significant differences in the time courses of a/APO2 and VI in both
<1,500 g group and ≥1,500 g group.
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Newfactan
Dand Surfacten
�group. 75% of the infants in Newfactan
�group
and 77% of the infants in Surfacten
� group received only one
dose of surfactant, and 23% of the infants in both Newfactan
�
group and Surfacten
� group received two doses. Only two
infants in Newfactan
�group received three doses of surfactant.
There was no significant difference in the response type to
surfactant between Newfactan
� group and Surfacten
� group.
The ‘Favorable’ type was observed in 84% of the infants in
Newfactan
� group and in 87% of the infants in Surfacten
�
group. The ‘Poor’ type was observed in 9% of the infants in
Newfactan
�group and 10% of the infants in Surfacten
�group.
The ‘Relapse’ type was observed in 7% of the infants in New-
factan
� group, and in 3% of the infants in Surfacten
� group.
The extubation rate by the 96 hr after surfactant instillation
was not significantly different between Newfactan
� group and
Surfacten
� group. 55% of the infants in Newfactan
� group,
and 52% of the infants in Surfacten
� group were extubated
by the 96 hr after surfactant instillation (Table 2). 
In ≥1,500 g group, the total doses of surfactant instilled
were not significantly different between Newfactan
� group
and Surfacten
� group (one dose 87 vs. 90%, two doses 13 vs.
10%). No infants in either group received three doses of sur-
factant. There was no significant difference in the response
type to surfactant between Newfactan
� group and Surfacten
�
group (‘Favorable’ 83 vs. 84%, ‘Poor’ 11 vs. 11%, ‘Relapse’
6 vs. 5%). The extubation rate by the 96 hr after surfactant
instillation was not significantly different between Newfac-
tan
� group and Surfacten
� group (83 vs. 89%) (Table 2).
The time courses of FiO2, MAP, a/APO2 and VI over the
96 hr after surfactant instillation were not significantly dif-
ferent between Newfactan
� group and Surfacten
� group in
both birth weight groups (Fig. 2, 3).
The incidences of air leak, patent ductus arteriosus, pul-
monary hemorrhage, and high-grade intraventricular hem-
orrhage, and short-term mortality during the 96 hr after sur-
factant instillation were not significantly different between
Newfactan
� group and Surfacten
� group in both birth weight
groups (Table 3).
Long-term outcome and complications
Total duration of intubation was not significantly different
between Newfactan
� group and Surfacten
�group (14.3±18.6
days versus 12.2±18.8 days) in <1,500 g group, as well as
in ≥1,500 g group (3.7±3.2 vs. 3.6±2.6 days). The inci-
dences of BPD and periventricular leukomalacia and the ulti-
mate mortality were not different between two surfactant
groups in both birth weight groups (Table 4).
DISCUSSION
Our data showed that there were no significant differences
in the efficacy in the treatment of RDS and in the incidence
of acute complications occurring around the surfactant instil-
lation therapy between Newfactan
�and Surfacten
�. In the ulti-
mate mortality and long-term complications including BPD
and periventricular leukomalacia, there were also no differ-
ences between the two surfactants.
There has been an urgent need for the clinical data that
could support the clinical comparability of Newfactan
�, a less
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1 Dose (%) 74 (75) 118 (77) 0.21 109 (87) 102 (90) 0.37
2 Doses (%) 23 (23) 35 (23) 0.21 16 (13) 12 (10) 0.37
3 Doses (%) 2 (2) 0 0.21 0 0 0.37
‘Favorable’  83 (84) 134 (87) 0.38 104 (83) 96 (84) 0.91
type (%)
‘Poor’ type (%) 9 (9) 15 (10) 0.38 14 (11) 13 (11) 0.91
‘Relapse’  7 (7) 5 (3) 0.38 7 (6) 5 (5) 0.91
type (%)
Extubation (%) 46 (55) 68 (52) 0.73 100 (83) 93 (89) 0.15
Table 2. Comparisons of the total doses of surfactant instillation,
the response type to surfactant, and extubation rate by the 96 hr
after surfactant instillation between Newfactan
� group and Sur-
facten
� group
<1,500 g (n=253)
p 
Newfactan
�
n=99
Surfacten
�
n=154
≥1,500 g (n=239)
p 
Newfactan
�
n=125
Surfacten
�
n=144
Air leak (%) 10 (10) 13 (9) 0.73 10 (8) 8 (7) 0.75
PDA (%) 62 (63) 82 (55) 0.24 26 (21) 34 (30) 0.11
PH (%) 16 (16) 15 (10) 0.13 4 (3) 2 (2) 0.48
High-grade  5 (5) 9 (7) 0.70 0 2 (2) 0.15
IVH (%)
Mortality (%) 11 (12) 15 (10) 0.67 5 (4) 5 (5) 0.87
Table 3. Comparisons of the incidences of acute complications
and short-term mortality during the 96 hr after surfactant instilla-
tion between Newfactan group and Surfacten
� group
<1,500 g (n=253)
p 
Newfactan
�
n=99
Surfacten
�
n=154
≥1,500 g (n=239)
p 
Newfactan
�
n=125
Surfacten
�
n=144
PDA, Patent ductus arteriosus; PH, Pulmonary hemorrhage; IVH, Intra-
ventricular hemorrhage.
Intubation 14.3± 12.2± 0.38 3.7± 3.6± 0.66
duration (d) 18.6 18.8 3.2 2.6
BPD* (%) 10 (13) 10 (9) 0.12 1 (1) 1 (0) 0.27
PVL* (%) 1 (1) 9 (8) 0.12 5 (5) 2 (2) 0.12
Mortality (%) 18 (20) 32 (24) 0.50 4 (4) 4 (4) 0.87
Table 4. Comparisons of the total duration of intubation, the inci-
dence of long-term complications, and the ultimate mortality
between Newfactan group and Surfacten
� group
<1,500 g (n=253)
p  Newfactan
�
n=99
Surfacten
�
n=154
≥1,500 g (n=239)
p 
Newfactan
�
n=125
Surfacten
�
n=144
BPD, Bronchopulmonary dysplasia; PVL, Periventricular leukomalacia.
*BPD and PVL was identified only in the infants who survived more than
28 days after birth.expensive domestically-developed surfactant, to Surfacten
�
for Newfactan
�to be used nation-wide as a primary pulmonary
surfactant agent in the treatment of RDS in Korea. The results
of the first clinical comparative study were already published
in 2000 (8). However, because it had a relatively small sam-
ple size and lacks the population of extremely low birth infants
whose birth weight was less than 800 g, further large-scale
clinical study has been required. Our study has a clinical sig-
nificance in that it is a multi-center study enrolled as many
as 492 newborn infants, especially 112 extremely low birth
weight infants whose birth weight was less than 1,000 g.
Although the data were not shown, like in <1,500 g group
and ≥1,500 g group, there were also no statistically signif-
icant difference in the short-term responses and acute com-
plications and long-term outcome and complications between
Newfactan
� group and Surfacten
� group in the subgroup of
infants whose birth weight was less than 1,000 g.
The two surfactants were alternatively allocated with strati-
fied block randomization, which is <1,500 g and ≥1,500 g
block. However, at a part of participating hospitals where the
infants with a birth weight of less than 1,500 g were in the
minority, the allocation was done without stratification. This
seems to be the origin of the size discrepancy between the two
surfactant groups in <1,500 g group. Due to the vague reliance
on Surfacten
� over Newfactan
�, the attending physicians seem
to have prescribed Surfacten
� instead of Newfactan
� in New-
factan’s turn of the original allocation order at those hospitals
when the birth weight of newly enrolled infant was less than
1,500 g, resulting in the disruption of the original allocation
order. This problem of disordered randomization may be a
major drawback of our study. Nevertheless, the results of our
study are not thought to be nullified. We also compared the
outcome by stratifying the subject infants by birth weight.
After the stratification, there were no statistically significant
differences in demographic and perinatal variables between
the two surfactant groups in both <1,500 g group and ≥
1,500 g group. This implicates that the two surfactant groups
in each stratum are similar in baseline conditions and there-
fore comparable to each other. Therefore, the results of our
study are considered to remain to be valid.
The reason why we stratified the subject infants by birth
weight is that the etiology and clinical course of RDS in each
subgroup were considered to be different. The etiology of
RDS in <1,500 g group may be primarily attributable to
absolute deficiency of pulmonary surfactant pool and its course
may be complicated due to a number of problems arising
from the prematurity itself. On the other hand, the etiology
of RDS in ≥1,500 g group may be more complex. Besides
the absolute deficiency of surfactant pool, conditions that lead
to secondary surfactant inactivation such as asphyxia, infec-
tion and aspiration of meconium or blood might be respon-
sible (1, 13). However, the clinical course of RDS in ≥1,500
g group may be, if not all, uncomplicated. Once the RDS has
resolved, the majority of infants in this group seem to go
uneventful until the discharge. This rationale for the strati-
fication seems to be partially validated by our data. The extu-
bation rate, the incidence of patent ductus arteriosus, pulmo-
nary hemorrhage, and high-grade intraventricular hemorrhage,
and short-term mortality during the 96 hr after surfactant
instillation, total duration of intubation, and the ultimate
mortality were significantly different between <1,500 g group
and ≥1,500 g group. However, contrary to our expectation,
the total doses of surfactant instillation and the response to
surfactant instillation therapy were not different between the
two birth weight groups. This stratification in the outcome
analyses are considered to have made our results more clini-
cally relevant.
In the time courses of a/APO2 and VI in ≥1,500 g group,
there is a tendency that respiratory status is aggravated again
later in the course after surfactant instillation. However, this
finding might have originated from the fact that a/APO2 and
VI were obtained only from the infants who took the blood
gas analysis. Because the infants who took blood gas analysis
until later in the course after surfactant instillation might
have had relatively severe and complicated course of RDS,
these later aggravations observed in the time courses of a/APO2
and VI might be the reflections of these infants.
In the present multi-center post-marketing comparative
study, Newfactan
�showed no differences in the efficacy in the
treatment of RDS and in the incidences of acute and long-term
complications, compared to Surfacten
�in both <1,500 g group
and ≥1,500 g group. 
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